AZ505: A Potent and Selective SMYD2 Inhibitor for Advanced Epigenetic and Cancer Biology Research

Executive Summary: AZ505 is a crystalline small molecule inhibitor that specifically targets SMYD2, a lysine methyltransferase implicated in the methylation of both histone and non-histone proteins (product information). It acts as a substrate-competitive inhibitor with an IC₅₀ of 0.12 μM, showing minimal off-target activity against related methyltransferases. AZ505 has demonstrated efficacy in suppressing SMYD2-driven processes in cancer, renal fibrosis, and inflammation models (reference study). It is recommended for immediate use in solution and should be stored as a solid at -20°C. APExBIO provides AZ505 (SKU: B1255) for translational and mechanistic studies of epigenetic regulation.

Biological Rationale

SMYD2 (SET and MYND domain-containing 2) is a protein lysine methyltransferase responsible for methylating histones H2B, H3, and H4, as well as tumor suppressors such as p53 and Rb (see DOI). Methylation of histone H3 at lysine 36 (H3K36) by SMYD2 regulates gene transcription and has been linked to the progression of cancers including gastric cancer and esophageal squamous cell carcinoma (ESCC). SMYD2 is also overexpressed in renal fibrosis and chronic kidney disease, making it a strategic target for both cancer biology research and epigenetic regulation research. The selective inhibition of SMYD2 is thus essential for dissecting disease-associated methylation events and their downstream effects.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a substrate-competitive SMYD2 inhibitor, binding to the peptide substrate groove on the SMYD2 protein and preventing substrate access (product information). Unlike cofactor-competitive inhibitors, AZ505 does not compete with S-adenosylmethionine (SAM), thereby preserving the enzyme's binding site for the methyl group donor. The compound exhibits an IC₅₀ of 0.12 μM and a K_i of 0.3 μM against SMYD2, with selectivity demonstrated by IC₅₀ values >83.3 μM for SMYD3, DOT1L, and EZH2. This selectivity minimizes off-target effects in cellular assays. The substrate-competitive mechanism means that AZ505 is most effective when substrate concentrations are within physiological ranges.

Evidence & Benchmarks

• AZ505 inhibits SMYD2 activity in vitro with an IC₅₀ of 0.12 μM, indicating high potency (product information).
• Selective inhibition is demonstrated by IC₅₀ values >83.3 μM for SMYD3, DOT1L, and EZH2, confirming minimal cross-reactivity (product documentation).
• In cisplatin-induced chronic kidney disease (CKD) models, AZ505 reduces SMYD2 expression, improves renal function, and decreases fibrosis and inflammation markers (study, Fig. 2–5).
• AZ505 inhibits the epithelial-mesenchymal transition (EMT) and the expression of fibrosis-related proteins and inflammatory cytokines in tubular epithelial cells in vitro (study, cell culture experiments).
• AZ505's substrate-competitive inhibition is confirmed by structural and enzymatic assays (APExBIO).

Compared to earlier guides such as AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic Research, this article provides updated evidence on AZ505's anti-fibrotic effects in renal models and clarifies selectivity benchmarks relevant for cross-disease applications. For expanded protocol guidance, see AZ505: Uncovering SMYD2 Inhibition in Kidney Fibrosis Models, which offers stepwise workflow suggestions but does not include recent CKD findings. The article AZ505: Potent and Selective SMYD2 Inhibitor in Translational Models reviews applications across model systems; the present article updates with the latest selectivity and efficacy data.

Applications, Limits & Misconceptions

AZ505 is primarily applied in cancer biology research, epigenetic regulation research, and studies of fibrotic diseases such as renal fibrosis. Its high selectivity for SMYD2 enables precise mechanistic studies in cell culture and animal models. AZ505 is particularly valuable in research on gastric cancer and ESCC, where SMYD2 overexpression is a critical pathogenic driver. In chronic kidney disease models, AZ505 prevents cisplatin-induced renal fibrosis and inflammation by modulating SMYD2-dependent signaling pathways, including Smad3 and STAT3 (reference study).

Common Pitfalls or Misconceptions

• AZ505 is not effective against methyltransferases other than SMYD2 at standard working concentrations; it cannot be used as a general methylation inhibitor (product page).
• Solutions of AZ505 are not stable for long-term storage; the compound should be prepared fresh before use (handling guidelines).
• AZ505 does not compete with S-adenosylmethionine, so effects may differ from cofactor-competitive inhibitors in pathway studies.
• In vivo efficacy and pharmacokinetics have not been fully validated for therapeutic applications; current use is research-only (limitations discussed).
• Some cell types may exhibit resistance if SMYD2 is not a key regulatory node; AZ505 should be used where SMYD2 is validated as a driver.

Workflow Integration & Parameters

• Stock Solution Preparation: Dissolve AZ505 in DMSO to a final concentration of 10 mM; filter-sterilize if required.
• Working Concentration: Use 0.1–5 μM in cell-based assays; titrate based on substrate and cell type (product recommendations).
• Storage: Store solid at -20°C; avoid repeated freeze-thaw cycles. Prepare solutions freshly before each experiment.
• Assay Timing: In cell assays, 24–72 hours of exposure is typical to observe SMYD2 pathway inhibition (reference protocol).
• Controls: Use DMSO vehicle controls and, where possible, an unrelated methyltransferase inhibitor as a selectivity benchmark.

Conclusion & Outlook

AZ505, a potent and selective SMYD2 inhibitor from APExBIO, is a critical reagent for advanced epigenetic research and disease modeling. Its substrate-competitive mechanism and high selectivity enable robust dissection of SMYD2-driven pathways in cancer and fibrotic disease contexts. Recent evidence underscores its translational value in renal fibrosis and inflammation models, though therapeutic development will require additional in vivo validation (reference). As the field advances, AZ505 will remain a reference compound for benchmarking new SMYD2-targeted strategies and elucidating disease mechanisms linked to aberrant methylation.